Search

everythinglearnresearchcommunity

for

Search:↓

The study created a 27-item measure to assess the impact of skin diseases.

VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.

Diagonal earlobe crease and lipoprotein(a) together help diagnose coronary heart disease.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

The VSCAPSI is a helpful method for evaluating the severity of scalp psoriasis.

Doppler ultrasonography can effectively detect blood flow changes in women with PCOS.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

The new scalp coverage scoring method accurately measures hair loss and growth in men.

Higher iron levels in hair may increase the risk of esophageal cancer.

Large databases in research can lead to misleading conclusions due to biases and chance findings; researchers should analyze data more rigorously.

Physical activity, height, and smoking affect prostate cancer risk.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

Certain hair and scalp features can predict the severity of alopecia areata.

Male pattern baldness may predict prostate cancer risk.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

Chronic scarring alopecia is common in SLE patients and needs early detection and management.

People with ankylosing spondylitis in Taiwan don't have a higher chance of getting alopecia.

Patients with cutaneous lupus erythematosus have a higher risk of skin cancer and other cancers.

Patients with mycosis fungoides have a higher risk of heart disease.

The Spanish HSS-29 scale effectively measures changes in life quality due to female-pattern hair loss.

Model improves accuracy in predicting hair loss effects.

Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.

Older people with severe COVID-19, especially those with certain health conditions, are more likely to experience post-COVID syndrome.

COVID-19 increased alopecia areata relapses due to inflammation and stress.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.